Company / Operating Cash Flow
Kura Oncology, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$64.1M
FY2025
5-year range
-$124.8M / $134.3M
FY2021-FY2025
Trend
-147.7%
vs FY2024
Sector context
#101 of 216
Health Care
What the data says
At -$64M, Kura Oncology, Inc.'s operating cash flow ranks #101 of 216 in the Health Care sector. Improved from -$125M to -$64M over the past 2 years.
Based on SEC 10-K filings.
-$64M in FY2025.
Improved from -$125M to -$64M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#101 of 216 in Health CareTop 47% of 216This company -$64.1M Sector average $658.7M
▼
-109.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 147.7% year-over-year.
- Ranks #101 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$64.1M | -147.7% |
| FY2024 | $134.3M | +207.6% |
| FY2023 | -$124.8M | -13.4% |
| FY2022 | -$110.1M | -5.3% |
| FY2021 | -$104.6M | -49.7% |
| FY2020 | -$69.8M | -27.5% |
| FY2019 | -$54.8M | -12.5% |
| FY2018 | -$48.7M | -71.1% |
| FY2017 | -$28.4M | -12.2% |
| FY2016 | -$25.3M | -41.4% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026